Rigel Pharmaceuticals

Rigel Pharmaceuticals

RIGL· Manufacturing· Fiscal year ends in December

No proxy on file names the CEO of Rigel Pharmaceuticals.

Executives5

See all
  1. 1Raul R. RodriguezFY2024
  2. 2Dean L. SchornoFY2022
  3. 3David A. SantosFY2022
  4. 4Raymond J. FureyFY2022
  5. 5Lisa Rojkjaer, M.D.FY2022

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Rigel Pharmaceuticals paid its one named executive on file $3.0M in FY2024 (Dec).

Name
Raul R. Rodriguez
Dean L. SchornoNot disclosedNot disclosed
David A. SantosNot disclosedNot disclosed
Raymond J. FureyNot disclosedNot disclosed
Lisa Rojkjaer, M.D.Not disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Rigel Pharmaceuticals. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Activity

Filings6

See all
Proxy statementDEF 14AApr 3, 2026FY2025
Annual report10-KMar 3, 2026FY2025
Proxy statementDEF 14AApr 10, 2025FY2024
Annual report10-KMar 4, 2025FY2024
Proxy statementDEF 14AApr 10, 2024FY2023
Annual report10-KMar 5, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data